PriceTargets.com logo

Verona Pharma - VRNA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $43.83
  • Forecasted Upside: 4.32%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$42.02 As of 12/20/2024 06:51 PM ET
▲ +0.8 (1.94%)

This chart shows the closing price for VRNA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Verona Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VRNA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VRNA

Analyst Price Target is $43.83
▲ +4.32% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Verona Pharma in the last 3 months. The average price target is $43.83, with a high forecast of $64.00 and a low forecast of $33.00. The average price target represents a 4.32% upside from the last price of $42.02.

This chart shows the closing price for VRNA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 6 contributing investment analysts is to buy stock in Verona Pharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/5/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$50.00 ➝ $64.00
11/5/2024HC WainwrightBoost TargetBuy ➝ Buy$36.00 ➝ $42.00
11/5/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$37.00 ➝ $44.00
10/9/2024Truist FinancialBoost TargetBuy ➝ Buy$38.00 ➝ $44.00
10/3/2024Wells Fargo & CompanyInitiated CoverageOverweight$50.00
10/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
9/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
9/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
7/22/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$35.00 ➝ $37.00
6/28/2024Truist FinancialBoost TargetBuy ➝ Buy$32.00 ➝ $38.00
6/27/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$35.00 ➝ $35.00
6/27/2024HC WainwrightBoost TargetBuy ➝ Buy$32.00 ➝ $36.00
5/13/2024HC WainwrightLower TargetBuy ➝ Buy$33.00 ➝ $30.00
4/16/2024Piper SandlerBoost TargetOverweight ➝ Overweight$31.00 ➝ $36.00
3/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$32.00
3/1/2024WedbushReiterated RatingOutperform ➝ Outperform$33.00
1/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$32.00
12/29/2023HC WainwrightReiterated RatingBuy ➝ Buy$32.00
11/2/2023WedbushReiterated RatingOutperform$33.00
10/19/2023WedbushReiterated RatingOutperform$33.00
9/13/2023WedbushReiterated RatingOutperform$30.00 ➝ $33.00
9/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$32.00
9/1/2023Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$35.00
8/4/2023WedbushReiterated RatingOutperform$30.00
8/4/2023HC WainwrightReiterated RatingBuy ➝ Buy$32.00
6/28/2023500.comReiterated RatingReiterates
6/7/2023Truist FinancialBoost Target$28.00 ➝ $32.00
3/20/2023BTIG ResearchBoost Target$26.00 ➝ $31.00
3/13/2023HC WainwrightReiterated RatingBuy$32.00
12/21/2022HC WainwrightBoost TargetBuy$30.00 ➝ $32.00
12/20/2022Truist FinancialBoost TargetBuy$20.00 ➝ $28.00
12/20/2022BTIG ResearchBoost TargetBuy$17.00 ➝ $26.00
9/19/2022WedbushReiterated RatingOutperform$27.00
8/29/2022HC WainwrightBoost TargetBuy$25.00 ➝ $30.00
8/26/2022Piper SandlerInitiated CoverageOverweight$31.00
8/10/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$24.00 ➝ $27.00
8/9/2022WedbushBoost Target$18.00 ➝ $23.00
6/21/2022HC WainwrightReiterated RatingBuy$25.00
6/17/2022WedbushLower TargetOutperform$25.00 ➝ $18.00
6/9/2022HC WainwrightReiterated RatingBuy$25.00
5/23/2022HC WainwrightReiterated RatingBuy$25.00
1/25/2022HC WainwrightReiterated RatingBuy$25.00
1/6/2022HC WainwrightReiterated RatingBuy$25.00
9/13/2021HC WainwrightInitiated CoverageBuy$25.00
6/13/2021BTIG ResearchReiterated RatingBuy$17.00
11/30/2020WedbushReiterated RatingBuy
8/25/2020Jefferies Financial GroupInitiated CoverageBuy$17.00
7/22/2020WedbushReiterated RatingBuy$23.00
4/21/2020WedbushLower TargetOutperform$60.00 ➝ $50.00
3/31/2020WedbushReiterated RatingBuy$60.00
2/28/2020WedbushReiterated RatingBuy$60.00
2/14/2020WedbushReiterated RatingBuy$60.00
1/14/2020SunTrust BanksBoost TargetBuy ➝ Buy$29.00 ➝ $34.00
1/13/2020WedbushBoost TargetOutperform$58.00 ➝ $60.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.43 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 9 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 7 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 5 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 3 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 11 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 13 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 22 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 26 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 26 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Verona Pharma logo
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $42.02
Low: $40.10
High: $42.86

50 Day Range

MA: $37.72
Low: $33.11
High: $42.68

52 Week Range

Now: $42.02
Low: $11.39
High: $43.73

Volume

733,684 shs

Average Volume

934,459 shs

Market Capitalization

$3.38 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.46

Frequently Asked Questions

What sell-side analysts currently cover shares of Verona Pharma?

The following sell-side analysts have issued stock ratings on Verona Pharma in the last twelve months: Canaccord Genuity Group Inc., HC Wainwright, Piper Sandler, Truist Financial Co., Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for VRNA.

What is the current price target for Verona Pharma?

0 Wall Street analysts have set twelve-month price targets for Verona Pharma in the last year. Their average twelve-month price target is $43.83, suggesting a possible upside of 4.3%. Wells Fargo & Company has the highest price target set, predicting VRNA will reach $64.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $33.00 for Verona Pharma in the next year.
View the latest price targets for VRNA.

What is the current consensus analyst rating for Verona Pharma?

Verona Pharma currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VRNA will outperform the market and that investors should add to their positions of Verona Pharma.
View the latest ratings for VRNA.

What other companies compete with Verona Pharma?

Other companies that are similar to Verona Pharma include Summit Therapeutics, Genmab A/S, Dr. Reddy's Laboratories, Sarepta Therapeutics and Catalent. Learn More about companies similar to Verona Pharma.

How do I contact Verona Pharma's investor relations team?

Verona Pharma's physical mailing address is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. The company's listed phone number is 011-44-0-2032834200 and its investor relations email address is [email protected]. The official website for Verona Pharma is www.veronapharma.com. Learn More about contacing Verona Pharma investor relations.